Resultats de la cerca - Mei Elsayed

  • Mostrar 1 - 3 resultats de 3
Refinar resultats
  1. 1
    Therapeutic Sequencing in ALK+ NSCLC

    Therapeutic Sequencing in ALK+ NSCLC per Mei Elsayed, Petros Christopoulos

    Publicat 2021
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  2. 2
    <i>EML4‐ALK</i> fusion variant V3 is a high‐risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK<sup>+</sup> non‐small cell lung cancer

    <i>EML4‐ALK</i> fusion variant V3 is a high‐risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK<sup>+</sup> non‐small c... per Petros Christopoulos, Volker Endris, Farastuk Bozorgmehr, Mei Elsayed, Martina Kirchner, Jonas Ristau, Ivo Buchhalter, Roland Penzel, Felix J.F. Herth, Claus Peter Heußel, Martin Eichhorn, Thomas Muley, Michael Meister, Jürgen R. Fischer, Stefan Rieken, Arne Warth, Helge Bischoff, Peter Schirmacher, Albrecht Stenzinger, Michael Thomas

    Publicat 2018
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  3. 3
    Identification of a highly lethal V3<sup>+</sup>TP53<sup>+</sup> subset in ALK<sup>+</sup> lung adenocarcinoma

    Identification of a highly lethal V3<sup>+</sup>TP53<sup>+</sup> subset in ALK<sup>+</sup> lung adenocarcinoma per Petros Christopoulos, Martina Kirchner, Farastuk Bozorgmehr, Volker Endris, Mei Elsayed, Jan Budczies, Jonas Ristau, Roland Penzel, Felix J.F. Herth, Claus Peter Heußel, Martin Eichhorn, Thomas Muley, Michael Meister, Jürgen R. Fischer, Stefan Rieken, Felix Lasitschka, Helge Bischoff, Rocı́o Sotillo, Peter Schirmacher, Michael Thomas, Albrecht Stenzinger

    Publicat 2018
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:

Eines de cerca: